10x Genomics Expands Leadership in Single Cell Analysis with …
WEBFeb 7, 2024 · 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X, the next generation of the company's leading single cell technology.
10x Genomics Reports Second Quarter 2024 Financial Results
WEBAug 8, 2024 · 10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $640 million to $660 million versus a prior range of $670 million to $690...
10x Genomics Announces Preliminary Fourth Quarter and Full …
WEBJan 8, 2024 · 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.
10x Genomics, Inc. (TXG) Latest Stock News & Headlines
WEBGet the latest 10x Genomics, Inc. (TXG) stock news and headlines to help you in your trading and investing decisions.
News - 10x Genomics
WEBIR Contact. Contact us by email at [email protected]. Email Alerts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order ...
10x Genomics to Showcase New Cutting-Edge Technologies and …
WEBFeb 5, 2024 · 10x Genomics will share new capabilities for its Chromium Flex assay, including: Whole blood fixation to directly fix whole blood for storage and later use with the Flex assay.
10X Genomics Inc (TXG) Stock Price & News - Google Finance
WEBGet the latest 10X Genomics Inc (TXG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
10x Genomics Reports Second Quarter 2024 Financial Results - PR …
WEBAug 8, 2024 · 10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $640 million to $660 million versus a prior range of $670 million to $690...
10x Genomics Poised for Growth: Buy Rating Affirmed ... - Markets …
WEBFeb 15, 2024 · 10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024; Canaccord still bullish on 10x Genomics, PacBio despite reducing 2024 estimates
12 Analysts Assess 10x Genomics: What You Need To Know
WEBJul 16, 2024 · Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $33.0, a high estimate of $55.00, and a low estimate of $16.00. Observing a downward trend, the current...